473
We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.
 adverse event: developed 
Please tell me event type and its trigger word from given type options. Output format is "type: trigger".  Option: adverse event, potential therapeutic event 
Text: {0} 
Answer:
 adverse event: developed 